Skip to main content
Sign in Create a free account
Varsity Tutors
Sign in

Monitoring Parameters (Labs And Vitals) - NAPLEX

  1. A 71-year-old male (70 kg, 170 cm) is hospitalized for acute decompensated heart failure and receives IV furosemide 80 mg twice daily. Current medications: furosemide IV, potassium chloride 20 mEq PO daily, enoxaparin 40 mg SC daily. Allergies: none. Labs this morning: Na 128 mEq/L (135–145), K 3.8 mEq/L (3.5–5.0), SCr 1.0 mg/dL (0.6–1.3). Vitals: BP 110/70 mmHg, HR 88 bpm. Which lab result suggests a need for intervention?
    Answer: Sodium 128 mEq/L Monitoring parameters for IV furosemide in heart failure include electrolytes to prevent imbalances like hyponatremia from excessive diuresis. The patient's sodium of 128 mEq/L indicates hyponatremia, which can cause neurological symptoms and requires intervention such as fluid restriction or dose adjustment. Sodium monitoring is optimal in this decompensated heart failure scenario with high-dose furosemide. Normal potassium, creatinine, and heart rate do not signal urgent issues. A transferable insight is to check electrolytes daily during aggressive diuresis. Best practice involves balancing diuresis with electrolyte replacement to avoid complications.
  2. A 63-year-old male (90 kg, 175 cm) with type 2 diabetes and CKD stage 3 is started on trimethoprim-sulfamethoxazole DS 1 tablet PO twice daily for cellulitis. Current medications: metformin 500 mg PO twice daily, lisinopril 40 mg PO daily, atorvastatin 40 mg PO nightly. Allergies: none. Baseline labs: SCr 2.0 mg/dL (0.6–1.3), eGFR 35 mL/min/1.73 m², K 4.8 mEq/L (3.5–5.0), AST 26 U/L (10–40), ALT 24 U/L (7–56). Vitals: BP 136/80 mmHg, HR 76 bpm. Which lab value should be monitored for this medication?
    Answer: Serum potassium concentration Monitoring parameters for trimethoprim-sulfamethoxazole in CKD patients emphasize electrolytes due to the risk of hyperkalemia from trimethoprim's potassium-sparing effects. The patient's CKD stage 3 (eGFR 35 mL/min/1.73 m²) and baseline potassium of 4.8 mEq/L increase the susceptibility to hyperkalemia. Serum potassium concentration should be monitored closely to detect and prevent elevations that could lead to arrhythmias. INR is not relevant without anticoagulant use, while serum amylase and troponin I are unrelated to this therapy's risks. A transferable insight is that in renal impairment, potassium monitoring is critical for drugs affecting renal potassium handling. Best practice includes checking potassium within 3-7 days of initiating such therapies in at-risk patients.
  3. A 48-year-old male (80 kg, 176 cm) with HIV is started on tenofovir disoproxil fumarate/emtricitabine plus dolutegravir. Current medications: TDF/FTC 1 tablet daily, dolutegravir 50 mg daily. Allergies: none. Baseline labs: SCr 1.0 mg/dL (0.6–1.3), eGFR 88 mL/min/1.73 m², phosphate 3.0 mg/dL (2.5–4.5), AST 24 U/L (10–40), ALT 22 U/L (7–56). Vitals: BP 122/76 mmHg, HR 72 bpm. Which lab value should be monitored for this medication?
    Answer: Serum creatinine/eGFR to monitor renal function Monitoring parameters for tenofovir disoproxil fumarate include renal function due to its potential for nephrotoxicity, such as Fanconi syndrome. The patient's baseline normal eGFR (88 mL/min/1.73 m²) still warrants monitoring given tenofovir's renal risks in HIV therapy. Serum creatinine/eGFR is optimal to detect early declines in renal function. INR, digoxin levels, and lipase are unrelated to tenofovir's toxicities. A best practice is to monitor renal function every 3-6 months during tenofovir use. Clinicians should also track phosphate levels for comprehensive renal assessment in at-risk patients.
  4. A 56-year-old female (74 kg) with bipolar disorder is maintained on lithium carbonate 300 mg PO three times daily. Current medications: lithium, levothyroxine 75 mcg PO daily, naproxen 220 mg PO twice daily as needed (started 1 week ago for knee pain). Allergies: none. Labs today: lithium level 1.6 mEq/L (therapeutic 0.6–1.2), SCr 1.3 mg/dL (0.6–1.2), sodium 134 mEq/L (135–145), thyroid-stimulating hormone (TSH) 6.8 mIU/L (0.4–4.0). Vital signs: BP 118/70 mmHg, HR 60 bpm. Which parameter indicates the need for a dose adjustment?
    Answer: Lithium level 1.6 mEq/L This question addresses monitoring lithium toxicity in the context of drug interactions affecting lithium clearance. The patient's lithium level of 1.6 mEq/L exceeds the therapeutic range (0.6-1.2 mEq/L), indicating toxicity likely precipitated by recently started naproxen. NSAIDs like naproxen reduce renal prostaglandin synthesis, decreasing lithium clearance by 20-25% and increasing serum levels. This elevated level requires immediate lithium dose reduction and possible temporary discontinuation until levels normalize. TSH of 6.8 mIU/L indicates hypothyroidism (common with chronic lithium use) but isn't the acute concern. Sodium of 134 mEq/L shows mild hyponatremia which can affect lithium levels but isn't the primary issue. Blood pressure is unrelated to lithium monitoring. When NSAIDs are necessary in lithium-treated patients, lithium dose should be preemptively reduced by 20-25% with close level monitoring, as this interaction is predictable and can precipitate severe toxicity including seizures, coma, and permanent neurologic damage.
  5. A 68-year-old male (76 kg, 171 cm) is being treated for complicated UTI with gentamicin. Current medications: gentamicin 5 mg/kg IV every 24 hours, ceftriaxone 1 g IV daily. Allergies: none. Labs: SCr increased from 1.0 to 1.6 mg/dL over 3 days (0.6–1.3), BUN 36 mg/dL (7–20), K 4.5 mEq/L (3.5–5.0). Vitals: BP 126/74 mmHg, HR 80 bpm. Which lab result suggests a need for intervention?
    Answer: Rising serum creatinine from 1.0 to 1.6 mg/dL Monitoring parameters for aminoglycosides like gentamicin include serum creatinine to detect nephrotoxicity, a dose-dependent adverse effect. The patient's rising SCr from 1.0 to 1.6 mg/dL over 3 days signals acute kidney injury, requiring intervention such as discontinuation. Rising creatinine monitoring is optimal in this UTI patient on gentamicin. Normal potassium, blood pressure, and absent ALT do not indicate issues. A transferable insight is to monitor renal function every 2-3 days during aminoglycoside therapy. Best practice involves using the lowest effective dose and duration to preserve kidney function.
  6. A 57-year-old female (62 kg, 160 cm) with hyperlipidemia is started on high-intensity atorvastatin 80 mg PO nightly after an ischemic stroke. Current medications: atorvastatin 80 mg nightly, clopidogrel 75 mg daily, amlodipine 5 mg daily. Allergies: none. Baseline labs: AST 38 U/L (10–40), ALT 41 U/L (7–56), CK 110 U/L (30–200), SCr 0.9 mg/dL (0.6–1.3). Vitals: BP 132/78 mmHg, HR 70 bpm. Which lab value should be monitored for this medication?
    Answer: Liver function tests (AST/ALT) if symptoms of hepatotoxicity occur Monitoring parameters for high-intensity statins like atorvastatin include liver function tests if symptoms of hepatotoxicity arise, due to rare but serious liver injury risk. The patient's baseline near-upper-limit AST/ALT (38/41 U/L) and high-dose therapy post-stroke necessitate symptom-guided monitoring. Liver function tests on symptoms is optimal to balance safety without unnecessary testing. Weekly INR or daily aPTT are irrelevant to statins, and lithium levels are not applicable. A transferable insight is that routine LFT monitoring is no longer recommended for statins unless clinically indicated. Best practice involves baseline LFTs and rechecking if muscle or liver symptoms occur.
  7. A 45-year-old female (70 kg) with focal seizures is seen in clinic for follow-up after a recent hospitalization for breakthrough seizures. Current medications: phenytoin extended-release 300 mg PO daily, sertraline 50 mg PO daily. Allergies: sulfonamides (rash). Labs today: total phenytoin 9 mcg/mL (10–20), albumin 2.4 g/dL (3.5–5.0), SCr 0.8 mg/dL (0.6–1.2), AST 22 U/L (10–40). Vital signs: BP 118/72 mmHg, HR 76 bpm. What follow-up test is necessary based on the current therapy to appropriately assess phenytoin exposure?
    Answer: Free (unbound) phenytoin concentration This question addresses monitoring phenytoin in the setting of hypoalbuminemia, where standard total phenytoin levels are misleading. The patient has a low albumin of 2.4 g/dL (normal 3.5-5.0), which significantly affects phenytoin protein binding since phenytoin is 90% albumin-bound. With hypoalbuminemia, more phenytoin remains unbound (free) and pharmacologically active, meaning the total level of 9 mcg/mL underestimates the true therapeutic effect. Free phenytoin concentration directly measures the active drug and is essential for appropriate dosing decisions in hypoalbuminemic patients. INR is irrelevant as phenytoin doesn't affect coagulation directly. Hemoglobin A1c monitors long-term glucose control, unrelated to phenytoin therapy. Serum magnesium, while important in some seizure disorders, isn't specifically indicated for phenytoin monitoring. The Winter-Tozer equation can estimate corrected phenytoin levels in hypoalbuminemia: Corrected phenytoin = Measured phenytoin / [(0.2 × albumin) + 0.1], but free phenytoin measurement remains the gold standard for accurate assessment.
  8. A 50-year-old male (78 kg, 172 cm) is admitted for acute mania and started on valproic acid 500 mg PO twice daily. Current medications: valproic acid, olanzapine 10 mg nightly. Allergies: none. Baseline labs: AST 44 U/L (10–40), ALT 52 U/L (7–56), platelets 145 x103x10^3/µL (150–400), ammonia 28 µmol/L (15–45). Vitals: BP 124/76 mmHg, HR 88 bpm. Which lab result suggests a need for intervention?
    Answer: Platelets 145 x103x10^3/µL Monitoring parameters for valproic acid include platelet count due to the risk of thrombocytopenia, especially at initiation. The patient's baseline platelets of 145 x103x10^3/µL are below normal (150–400), suggesting potential early suppression requiring intervention. Platelet monitoring is optimal to prevent bleeding in this acute mania patient. Normal ammonia, blood pressure, and heart rate are not concerns. A transferable insight is to check CBC periodically during valproic acid therapy for hematologic effects. Best practice involves avoiding valproic acid if platelets are low and considering alternatives like lithium.
  9. A 65-year-old male (83 kg, 174 cm) with hypertension and BPH is started on tamsulosin 0.4 mg PO daily. Current medications: tamsulosin, losartan 50 mg daily. Allergies: none. Labs: SCr 1.0 mg/dL (0.6–1.3), K 4.2 mEq/L (3.5–5.0). Vitals sitting: BP 132/78 mmHg, HR 72 bpm; standing: BP 110/68 mmHg, HR 88 bpm. What is the most critical vital sign to assess in this scenario?
    Answer: Orthostatic blood pressure and heart rate to assess for symptomatic hypotension Monitoring parameters for alpha-blockers like tamsulosin involve assessing vital signs to detect orthostatic hypotension, a common adverse effect that can lead to falls or syncope. The patient's concomitant use of losartan for hypertension and his age increase the risk of hypotensive episodes, making postural changes a key factor in monitoring decisions. Orthostatic blood pressure and heart rate are optimal to assess here, as the observed drop from 132/78 mmHg sitting to 110/68 mmHg standing, with heart rate increase, indicates potential symptomatic hypotension requiring intervention. Temperature monitoring for drug fever is suboptimal, as tamsulosin is not commonly associated with this side effect. Oxygen saturation and respiratory rate are irrelevant, as tamsulosin does not typically cause hypoxemia or bronchospasm. Clinically, always evaluate orthostatic vitals in patients starting alpha-blockers, especially those on antihypertensives, to prevent complications like dizziness or injury. This practice applies broadly to therapies with vasodilatory effects, promoting proactive monitoring to enhance patient safety.
  10. A 64-year-old male (78 kg) with atrial fibrillation is seen in an anticoagulation clinic. Current medications: warfarin 5 mg PO daily, amiodarone 200 mg PO daily (started 10 days ago), atorvastatin 40 mg PO nightly. Allergies: none. Labs today: INR 4.6 (goal 2.0–3.0), hemoglobin 13.8 g/dL (13.5–17.5), AST 30 U/L (10–40), SCr 1.0 mg/dL (0.6–1.2). Vital signs: BP 122/70 mmHg, HR 68 bpm. Which parameter indicates the need for a dose adjustment?
    Answer: INR 4.6 This question addresses drug interaction monitoring between warfarin and amiodarone, a potent CYP2C9 inhibitor. The patient's INR of 4.6 significantly exceeds the therapeutic range of 2.0-3.0 for atrial fibrillation, placing him at high bleeding risk. Amiodarone, started 10 days ago, inhibits warfarin metabolism through CYP2C9 and CYP3A4 inhibition, typically increasing INR by 50-100% within 1-2 weeks. This supratherapeutic INR requires immediate warfarin dose reduction, typically by 25-40%, with close INR monitoring. AST of 30 U/L is normal and doesn't indicate hepatotoxicity. SCr of 1.0 mg/dL shows normal kidney function. Hemoglobin of 13.8 g/dL is within normal range and doesn't suggest bleeding yet. When initiating amiodarone in patients on warfarin, preemptive warfarin dose reduction by 30-50% is often recommended with INR checks every 2-3 days initially, as this interaction is predictable and significant, potentially persisting for weeks after amiodarone discontinuation due to its long half-life.
  11. A 62-year-old male (84 kg, 175 cm) with gout is started on allopurinol 100 mg PO daily. Current medications: allopurinol, hydrochlorothiazide 25 mg daily, naproxen 250 mg PO twice daily as needed. Allergies: none. Baseline labs: SCr 2.2 mg/dL (0.6–1.3), eGFR 32 mL/min/1.73 m², uric acid 9.8 mg/dL (3.5–7.2). Vitals: BP 138/82 mmHg, HR 76 bpm. Which parameter indicates the need for a dose adjustment?
    Answer: Reduced eGFR/SCr elevation indicating need for renal dose adjustment Monitoring parameters for allopurinol include dose adjustment based on renal function to prevent toxicity like hypersensitivity syndrome. The patient's reduced eGFR (32 mL/min/1.73 m²) and elevated SCr (2.2 mg/dL) require starting at a lower dose than standard. Reduced eGFR/SCr elevation indicates the need for renal dose adjustment in this gout patient. Normal heart rate, ALT, and absent INR do not drive adjustments. A best practice is to cap allopurinol at 100 mg daily for eGFR <30 mL/min. Clinicians should monitor uric acid levels to assess efficacy post-adjustment.
  12. A 58-year-old female (68 kg, 162 cm) with rheumatoid arthritis is taking methotrexate 20 mg PO once weekly and folic acid 1 mg PO daily. Current medications: methotrexate, folic acid, ibuprofen 400 mg PO three times daily as needed. Allergies: none. Labs today: AST 78 U/L (10–40), ALT 92 U/L (7–56), SCr 0.9 mg/dL (0.6–1.3), WBC 4.2 x103x10^3/µL (4.0–11.0), platelets 165 x103x10^3/µL (150–400). Vitals: BP 124/74 mmHg, HR 70 bpm. Which lab result suggests a need for intervention?
    Answer: Elevated AST/ALT above normal range Monitoring parameters for methotrexate include liver function tests to detect hepatotoxicity, a common adverse effect with chronic use. The patient's elevated AST (78 U/L) and ALT (92 U/L) suggest possible liver injury, warranting intervention such as dose reduction or discontinuation. Elevated AST/ALT is optimal to monitor as it directly indicates hepatotoxicity risk in this rheumatoid arthritis patient on weekly methotrexate. Normal serum creatinine, platelet count, and blood pressure do not signal methotrexate-related toxicities like nephrotoxicity or myelosuppression here. A best practice is to perform liver function tests every 1-3 months during methotrexate therapy. Clinicians should supplement with folic acid to mitigate some toxicities while monitoring for cumulative effects.
  13. A 72-year-old female (60 kg, 160 cm) with heart failure with reduced ejection fraction is evaluated 1 week after discharge. Current medications: furosemide 40 mg PO twice daily, lisinopril 20 mg PO daily, carvedilol 12.5 mg PO twice daily, potassium chloride 20 mEq PO daily. Allergies: none. Labs today: sodium 132 mEq/L (135–145), potassium 2.9 mEq/L (3.5–5.0), SCr 1.1 mg/dL (0.6–1.2). Vital signs: BP 110/68 mmHg, HR 64 bpm. Which lab result suggests a need for intervention related to her current therapy?
    Answer: Potassium 2.9 mEq/L This question evaluates monitoring for diuretic-induced electrolyte abnormalities in heart failure management. The patient's potassium of 2.9 mEq/L is below the normal range (3.5-5.0 mEq/L), representing significant hypokalemia from furosemide therapy despite daily potassium supplementation. This critically low potassium level increases risk of cardiac arrhythmias, particularly concerning in heart failure patients who may already have arrhythmogenic substrate. Immediate intervention is needed to increase potassium supplementation and possibly reduce furosemide dose. Sodium of 132 mEq/L represents mild hyponatremia but is less immediately dangerous than hypokalemia. SCr of 1.1 mg/dL is within normal limits and doesn't indicate renal dysfunction. Heart rate of 64 bpm is appropriate for a patient on carvedilol and indicates good beta-blocker effect. In heart failure patients on loop diuretics, maintaining potassium >4.0 mEq/L is ideal to reduce arrhythmia risk, and levels <3.0 mEq/L require urgent correction with close monitoring.
  14. A 61-year-old male (85 kg) with rheumatoid arthritis is taking methotrexate 15 mg PO once weekly with folic acid 1 mg PO daily. Current medications: methotrexate, folic acid, omeprazole 20 mg PO daily. Allergies: none. Labs today: AST 78 U/L (10–40), ALT 92 U/L (7–56), SCr 1.0 mg/dL (0.6–1.2), platelets 210 ×10310^3/mm³ (150–450). Vital signs: BP 124/76 mmHg, HR 74 bpm. Which lab result suggests a need for intervention related to his current therapy?
    Answer: ALT 92 U/L This question tests monitoring for methotrexate hepatotoxicity, a common adverse effect requiring dose modification or discontinuation. The patient's ALT of 92 U/L exceeds the upper limit of normal (7-56 U/L) by more than 1.5-fold, and AST of 78 U/L is nearly double the upper limit (10-40 U/L), indicating hepatocellular injury from methotrexate. These elevations warrant immediate intervention - either dose reduction, temporary discontinuation, or increased folic acid supplementation. SCr of 1.0 mg/dL shows normal kidney function important for methotrexate clearance. Platelets of 210 ×10³/mm³ are normal; thrombocytopenia would be concerning but isn't present. Blood pressure is unrelated to methotrexate monitoring. Guidelines recommend checking liver enzymes every 4-8 weeks during methotrexate therapy, with dose reduction for persistent elevations >2× ULN or discontinuation for >3× ULN, as chronic methotrexate use can lead to hepatic fibrosis and cirrhosis.
  15. A 52-year-old female (62 kg) with schizophrenia is initiated on clozapine 25 mg PO nightly, titrating upward, after inadequate response to other antipsychotics. Current medications: clozapine, docusate 100 mg PO twice daily, nicotine patch 21 mg daily. Allergies: penicillin (hives). Baseline labs: absolute neutrophil count (ANC) 2,100 cells/mm³ (≥1,500), white blood cell count 5.0 ×10310^3/mm³ (4.0–11.0), AST 18 U/L (10–40), SCr 0.9 mg/dL (0.6–1.2). Vital signs: BP 116/74 mmHg, HR 88 bpm. Which lab value should be monitored for this medication to reduce the risk of serious adverse effects?
    Answer: Absolute neutrophil count (ANC) This question tests knowledge of clozapine's black box warning for agranulocytosis requiring mandatory hematologic monitoring. Clozapine uniquely requires absolute neutrophil count (ANC) monitoring due to its 1-2% risk of potentially fatal agranulocytosis, typically occurring within the first 18 weeks of therapy. The FDA mandates weekly ANC monitoring for the first 6 months, biweekly for months 6-12, then monthly thereafter through the Clozapine REMS program. Treatment must be discontinued if ANC falls below 1,000 cells/mm³. Serum sodium isn't specifically affected by clozapine. INR monitoring isn't required as clozapine doesn't affect coagulation. Hemoglobin A1c, while potentially relevant given clozapine's metabolic effects, isn't the critical safety monitoring parameter. The patient's baseline ANC of 2,100 cells/mm³ is adequate to start therapy (must be ≥1,500), but vigilant monitoring is essential to detect early neutropenia and prevent progression to agranulocytosis, which can be irreversible and fatal without prompt discontinuation.
  16. A 69-year-old female (72 kg, 158 cm) with hypertension is started on spironolactone 25 mg PO daily for resistant hypertension. Current medications: amlodipine 10 mg daily, losartan 100 mg daily, spironolactone 25 mg daily. Allergies: none. Baseline labs: K 4.9 mEq/L (3.5–5.0), SCr 1.2 mg/dL (0.6–1.3), eGFR 52 mL/min/1.73 m². Vitals: BP 154/88 mmHg, HR 72 bpm. Which lab value should be monitored for this medication?
    Answer: Serum potassium concentration Monitoring parameters for spironolactone include serum potassium due to its potassium-sparing effects, which can cause hyperkalemia. The patient's baseline potassium of 4.9 mEq/L and reduced eGFR (52 mL/min/1.73 m²) heighten the risk of hyperkalemia in this hypertensive setting. Serum potassium concentration should be monitored to detect elevations promptly. Serum amylase, INR, and uric acid are not primary concerns for spironolactone. A transferable insight is to check potassium within 1 week of starting aldosterone antagonists in renal impairment. Best practice includes avoiding concurrent potassium supplements unless necessary and educating on dietary potassium restriction.
  17. A 73-year-old female (58 kg, 155 cm) with osteoporosis is started on alendronate 70 mg PO once weekly. Current medications: alendronate, calcium carbonate 500 mg elemental calcium PO twice daily, vitamin D3 1,000 units PO daily. Allergies: none. Labs: calcium 8.1 mg/dL (8.6–10.2), 25-hydroxyvitamin D 18 ng/mL (20–50), SCr 1.0 mg/dL (0.6–1.3). Vitals: BP 118/66 mmHg, HR 72 bpm. Which lab result suggests a need for intervention?
    Answer: 25-hydroxyvitamin D 18 ng/mL Monitoring parameters for bisphosphonates like alendronate include vitamin D levels to ensure adequate absorption and prevent hypocalcemia. The patient's low 25-hydroxyvitamin D (18 ng/mL) indicates deficiency, warranting supplementation before or with alendronate. Vitamin D monitoring is optimal to optimize therapy in this osteoporosis patient. Normal creatinine, heart rate, and absent INR are irrelevant. A best practice is to correct vitamin D deficiency to >30 ng/mL before starting bisphosphonates. Clinicians should combine with calcium and monitor bone density for efficacy.
  18. A 52-year-old female (85 kg, 168 cm) with bipolar disorder is taking lithium carbonate 900 mg/day (300 mg PO three times daily). She reports new nausea, tremor, and diarrhea after starting hydrochlorothiazide 25 mg PO daily 1 week ago for hypertension. Current medications: lithium, hydrochlorothiazide, quetiapine 100 mg PO nightly. Allergies: none. Labs: SCr 1.3 mg/dL (0.6–1.3), Na 134 mEq/L (135–145), K 3.7 mEq/L (3.5–5.0). Vitals: BP 112/68 mmHg, HR 86 bpm. Which follow-up test is necessary based on the current therapy?
    Answer: Serum lithium concentration (12-hour trough) Monitoring parameters for lithium include serum concentrations to ensure therapeutic levels and avoid toxicity, especially with drug interactions. The patient's new hydrochlorothiazide use can increase lithium levels by reducing renal clearance, contributing to symptoms like nausea, tremor, and diarrhea. Serum lithium concentration (12-hour trough) is optimal to confirm toxicity and guide dose adjustment in this bipolar patient. INR, troponin, and fasting lipids are unrelated to lithium's risks. A transferable insight is to check lithium levels 5-7 days after diuretic initiation due to interaction risks. Best practice involves monitoring renal function and electrolytes alongside lithium levels for comprehensive safety.
  19. A 43-year-old female (64 kg, 163 cm) is started on isotretinoin for severe nodular acne. Current medications: isotretinoin 40 mg PO twice daily (new). Allergies: none. Medical history: hypertriglyceridemia. Baseline labs: triglycerides 320 mg/dL (<150), AST 34 U/L (10–40), ALT 36 U/L (7–56), pregnancy test negative. Vitals: BP 116/70 mmHg, HR 74 bpm. Which lab value should be monitored for this medication?
    Answer: Fasting lipid panel (including triglycerides) Monitoring parameters for isotretinoin include fasting lipid panels due to the risk of hypertriglyceridemia, especially in patients with baseline elevations. The patient's high triglycerides (320 mg/dL) and history of hypertriglyceridemia necessitate close monitoring to prevent pancreatitis. Lipid panel monitoring is optimal for safe isotretinoin use in this acne patient. INR, potassium, and digoxin are unrelated. A best practice is to check lipids monthly during isotretinoin therapy. Clinicians should counsel on low-fat diets and consider dose reduction if triglycerides exceed 500 mg/dL.
  20. A 66-year-old male (92 kg, 180 cm) is receiving unfractionated heparin IV infusion for acute pulmonary embolism. Current medications: heparin infusion per protocol, aspirin 81 mg PO daily. Allergies: none. Labs: aPTT 98 seconds (target per protocol typically ~60–80 seconds), platelets 210 x103x10^3/µL (150–400), hemoglobin 13.8 g/dL (13.5–17.5), SCr 1.0 mg/dL (0.6–1.3). Vitals: BP 118/72 mmHg, HR 82 bpm. Which parameter indicates the need for a dose adjustment?
    Answer: aPTT 98 seconds Monitoring parameters for unfractionated heparin include aPTT to ensure therapeutic anticoagulation without excessive bleeding risk. The patient's aPTT of 98 seconds exceeds the typical target (60–80 seconds), indicating supratherapeutic levels requiring dose reduction. aPTT monitoring is optimal for adjusting the infusion in this pulmonary embolism case. Normal platelets, creatinine, and absent ALT do not necessitate changes. A best practice is to check aPTT every 6 hours until stable, then daily. Clinicians should use weight-based protocols for initial dosing to optimize therapy.

Start this quiz